Literature DB >> 29625880

Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?

Colin D Weekes1, Jeffrey W Clark1, Andrew X Zhu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29625880     DOI： 10.1016/S1470-2045(18)30249-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

1.  ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance.

Authors:  Xudong Gao; Hebing Chen; Xin Huang; Hao Li; Zhen Liu; Xiaochen Bo
Journal:  Onco Targets Ther       Date:  2019-02-26       Impact factor: 4.147

2.  Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.

Authors:  Kai Wei; Mao Li; Margot Zöller; Meng Wang; Arianeb Mehrabi; Katrin Hoffmann
Journal:  Cell Death Dis       Date:  2019-03-08       Impact factor: 8.469

3.  Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling.

Authors:  Yukun Wu; Zhizhang Li; Lijuan Zhang; Guiyang Liu
Journal:  Med Sci Monit       Date:  2019-10-02

Review 4.  Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?

Authors:  Shankun Zhao; Weizhou Wu; Hao Jiang; Lei Ma; Chengyi Pan; Chong Jin; Jinggang Mo; Liezhi Wang; Kunpeng Wang
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

5.  MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines.

Authors:  Wafaa M Rashed; Mohamed A Kandeil; Mohamed O Mahmoud; Doha Maher; Sameera Ezzat; Mohamed H Abdel-Rahman
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-26       Impact factor: 4.553

Review 6.  New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment.

Authors:  Jiajia Zhang; Shafat Quadri; Christopher L Wolfgang; Lei Zheng
Journal:  Biomedicines       Date:  2018-08-13

7.  Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non-small-cell lung cancer: A meta-analysis based on randomized controlled trials.

Authors:  Huan Deng; Li Wang; Xinling Chen; Shujuan Zhang; Fengming Yi; Yiping Wei; Wenxiong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

Review 8.  Emerging agents and regimens for hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Hui-Chuan Sun
Journal:  J Hematol Oncol       Date:  2019-10-26       Impact factor: 17.388
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.